In Vitro Induction of Lymphokine-Activated Killer (Lak) Activity in Patients with Neuroblastoma

References

• Berthold F, Brandeis W E, Lampert F. Neuroblastoma: Diagnostic advances and therapeutic results in 370 patients. Malignant Neoplasms in Childhood and Adolescence, H. Riehm. Karger, Basel 1986; vol. 18: 206–223, Monogr. Paediat.
   Google Scholar
• Carlsen N LT, Schroeder H, Bor P V, Erichsen G, Hamborg-Petersen B, Jensen K B, Nielsen O A. Neuroblastomas treated at the four major child oncologic clinics in Denmark, 1943–1980: An evaluation of 180 cases. Med Paediatr., Oncol 1986; 13: 180–186
   Google Scholar
• Ninane J, Pritchard J, Malpas J S. Chemotherapy of advanced neuroblastoma: Does adriamycin contribute. Arch Dis Childh 1981; 56: 544–548
   PubMed Web of Science ®Google Scholar
• Rosen E M, Cassady J R, Frantz C N, Kretschmar C, Levey R, Sallan S E. Neuroblastoma: The joint center for radiation therapy/Dana-Farber Cancer Institute/Children's Hospital Experience. J Clin Oncol 1984; 2: 719–732
   PubMed Web of Science ®Google Scholar
• Treuner J, Gerein V, Klingebiel T, Schwabe D, Feine U, Happ J, Niethammer D, Maul F, Dopfer R, Komhuber B, Berthold F, Jürgens H, Hor G. MIBG-treatment in neuroblastoma: Experiences of the Tubingen/Frankfurt group. Advances in Neuroblastoma Research 2, A. E. Evans, G. J. D'Angio, A. G. Knudson, R. C. Seeger. Alan R. Liss, New York 1988; 669–678
   Google Scholar
• Pritchard J, McElwain T J, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J. Cancer 1982; 45: 86–94
   Web of Science ®Google Scholar
• D'Angio G J, August C, Elkins W, Evans A E, Seeger R, Feig S, Lenarsky C, Wells J, Ramsay N, Kim T, Woods W, Krivit W, Strandjord S, Coccia P, Novak L. Metastatic neuroblastoma managed by supralethal therapy and bone marrow reconstitution (BMRC). Results of a four institution children's cancer study group pilot study. Advances in Neuroblastoma Research, A. E. Evans. Alan R. Liss, New York 1985; 565–568
   Google Scholar
• Philip T., Bernard J L, Zucker J M, Pinkerton R, Lutz P, Bordigoni P, Plouvier E, Robert A, Carton R, Philippe N, Philip I, Chauvin F, Favrot M. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma. An unselected group of stage IV patients over 1 year of age. J Clin Oncol 1987; 5: 266–271
   PubMed Web of Science ®Google Scholar
• Hartmann O, Kalifa C, Benhamou E, Patte C, Flamamt F, Julien C, Beaujean F, Lemerle J. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 1986; 16: 165–169
   PubMed Web of Science ®Google Scholar
• Hartmann O, Benhamou E, Beaujean F, Kalifa C, Lejars O, Patte C, Behard C, Flamant F, Thyss A, Deville A, Vannier J P, Pautard-Muchemble B, Lemerle J. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma. J Clin Oncol 1987; 5: 1205–1211
   PubMed Web of Science ®Google Scholar
• Berthold F, Bender-Gotze C H, Dopfer R, Erttman R, Haas R J, Henze G, Korbling M, Riehm H, Rister M, Stollman B, Niethammer D. Myeloablative chemoradiotherapy and autologous and allogeneic bone marrow reconstitution in children with metastatic neuroblastoma. Klin Paediatr 1988; 200: 221–225
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Lotze M T, Muul L M, Chang A E, Avis F P, Leitman S, Linehan W M, Robertson C N, Lee R E, Rubin J T, Seipp C A, Simpson C G, White D E. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interkeukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• West W H, Tauer K W, Yanelli J R, Marshall G D, Orr D W, Thurman G B, Oldham R K. Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905
   PubMed Web of Science ®Google Scholar
• Boyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21: 51, suppl. 97
   Google Scholar
• Lozzio C B, Lozzio B B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1972; 45: 321–334
   Google Scholar
• Gilbert F, Balaban-Malenbaum G. Genetic regulation of malignancy in human neuroblastoma cell hybrids. advances in Neuroblastoma Research, A. E. Evans. Raven Press, New York 1980; 59–72
   Google Scholar
• Biedler J L, Helson L, Spengler B A. Human neuroblastoma cells in continuous culture: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973; 33: 2643–2652
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Kimmig A, Lang P, Daurer B, Kuci S, Bruchelt G, Treuner J, Niethammer D. Interferon-gamma upregulates the suspeptibility of human neuroblastoma cells to interleukin 2-activated natural killer cells. Nat Immun Cell Growth Regul, accepted for publication
   Google Scholar
• Gerson J M, Herberman R B. Systemic and in situ natural killer activity in patients with neuroblastoma. Advances in Neuroblastoma Research, A. E. Evans. Raven Press, New York 1980; 251–259
   Google Scholar
• Lotzova E, Savary S A, Herberman R B. Impaired NK cell profile in leukemia patients. Immunobiology of Natural Killer Cells, E. Lotzova, R. B. Herberman. Karger, Basel 1986; vol. II: 26–34
   Google Scholar
• Nasrallah A G, Miale T D. Decreased natural killer cell activity in children with untreated acute leukemia. Cancer Res 1983; 43: 5580–5585
   PubMed Web of Science ®Google Scholar
• Anderson P M, Bach F M, Ochoa A C. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD 3 and interleukin-2. Cancer Immunol Immunother 1988; 27: 82–88
   PubMed Web of Science ®Google Scholar
• Adler A, Chervenik P A, Whiteside T L, Lotzova E, Herberman R B. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Ades E W, Peacocke N, Sabio H. Lymphokine-activated killer cell lysis of human neuroblastoma cells: A model for purging tumor cells from bone marrow. Clin Immunol Immunopath 1988; 46: 48–54
   Google Scholar